See Our Latest Insights
on the impacts of COVID-19.

$144 Million

Oncopeptides AB

PIPE

Bookrunner, May 2020

Directed Share Issue

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti-cancer research to develop treatments for the benefit of patients. Oncopeptides’ lead product candidate is Ygalo (melflufen), the first peptidase potentiated cytotoxic therapy intended for use in the treatment of multiple myeloma.

More Like This

Mar 2020
$65 Million
DermTech logo

PIPE

Lead Placement Agent

View Details
Nov 2019
A$120 Million (aud)

Institutional Placement

Financial Advisor

View Details
Nov 2019
$20 Million

PIPE

Lead Placement Agent

View Details